Abivax colitis drug hits goal, but cancer cases rattle investors
Decision brief
Answer first · skim in under a minute
Abivax's obefazimod met primary efficacy endpoints in a late-stage ulcerative colitis trial, but three cancer cases among treated patients sent shares down 27%. The safety signal, deemed unrelated by investigators, creates uncertainty for regulatory filings and partnership discussions.
Abivax colitis drug hits goal in Phase 3 ulcerative colitis maintenance: both 25 mg and 50 mg obefazimod beat placebo on Week 44 clinical remission, while one prostate cancer, one breast cancer, and one colonic dysplasia case on the high dose rattled investors ahead of a planned late-2026 FDA filing.
Contents10 sections
Key Takeaways
- At Week 44, 25 mg and 50 mg obefazimod delivered placebo-adjusted clinical remission of 39.3% and 40.3% (50.8% and 51.3% vs 10.4% placebo; p<0.0001).
- Among 580 re-randomized induction responders, investigators called the three non-NMSC malignancy findings on 50 mg unrelated to treatment.
- Abivax plans an ulcerative colitis NDA in late Q4 2026; ABTECT trials are registered as NCT05507203, NCT05507216, and NCT05535946.
- Serious TEAEs were 4.2% on placebo, 2.6% on 25 mg, and 5.6% on 50 mg, with no deaths in the maintenance dataset.
What did the ABTECT maintenance trial show?
On June 1, 2026, Abivax reported topline results from the Phase 3 ABTECT 44-week maintenance trial of oral once-daily obefazimod, a miR-124 enhancer, in moderately to severely active ulcerative colitis. Induction responders (N=580) were re-randomized to 25 mg, 50 mg, or placebo.
Both doses met the FDA primary endpoint. Clinical remission at Week 44 reached 98 of 193 patients (50.8%) on 25 mg and 100 of 195 (51.3%) on 50 mg, versus 20 of 192 (10.4%) on placebo, per Abivax’s SEC Exhibit 99.1.
How large were the secondary endpoint gains?
Both doses also met key secondary endpoints, including endoscopic improvement, endoscopic remission, histologic-endoscopic mucosal improvement (HEMI), corticosteroid-free clinical remission, and sustained clinical remission.
Placebo-adjusted endoscopic improvement was 42.5% at 25 mg and 51.0% at 50 mg. Placebo-adjusted endoscopic remission was 31.4% and 37.8%. Those figures come from the same June 1, 2026 disclosure furnished with Abivax’s Form 6-K.
What safety findings accompanied the efficacy win?
Abivax described an overall favorable safety profile with no new signals and no deaths. Any TEAE rates were 50.0% (placebo), 58.0% (25 mg), and 71.8% (50 mg). Serious TEAEs were 4.2%, 2.6%, and 5.6%.
- Non-NMSC malignancies on 50 mg: prostate cancer 1 (0.5%), breast cancer 1 (0.5%), colonic dysplasia 1 (0.5%); zero on placebo and 25 mg.
- Investigators judged the prostate, breast, and colon findings unrelated to treatment and reported no organ-specific clustering.
- NMSC events included basal and squamous cell carcinomas, with mean age 62 years versus 42 years in the overall trial population.
Why did markets react despite meeting the primary endpoint?
Investors focused on the high-dose malignancy rows even though Abivax framed them as background events. The company still said it remains on track for an ulcerative colitis NDA in late Q4 2026. Market moves and bank target changes are not verified in the SEC package, so this report does not treat price drops or analyst downgrades as primary facts.
For BD and competitive intelligence teams, the efficacy bar is high, but partnership diligence will center on the integrated malignancy database and any FDA feedback on labeling or pharmacovigilance.
Where is the trial program registered?
Abivax says the global UC program is evaluating more than 1,200 patients across three pivotal trials. Registry identifiers listed in the company disclosure are NCT05507203, NCT05507216, and NCT05535946 on ClinicalTrials.gov.
Obefazimod (ABX464) remains investigational. Crohn’s disease Phase 2b induction topline data are expected mid-year 2027, according to the same June 1, 2026 update.
What remains unproven after the Week 44 readout?
Meeting maintenance endpoints in induction responders does not by itself prove first-line superiority versus approved oral or biologic UC drugs in head-to-head trials. Independent peer-reviewed publication of the full ABTECT maintenance dataset is still pending.
Regulators may still request additional nonclinical, carcinogenicity, or post-marketing safety commitments even if investigators called the three non-NMSC cases unrelated. Until the FDA reviews the NDA package, malignancy risk-benefit remains a company interpretation, not an agency conclusion.
Related NovaPharma coverage
- Abivax UC drug efficacy and cancer concerns
- Obefazimod ABTECT: remission vs safety watch
- J&J Phase 3 Tremfya data in ulcerative colitis
Frequently Asked Questions
Did Abivax's colitis drug hit its Phase 3 goal?
Yes. In the Phase 3 ABTECT maintenance trial, both 25 mg and 50 mg once-daily obefazimod met the FDA primary endpoint of clinical remission at Week 44, with placebo-adjusted rates of 39.3% and 40.3% versus a 10.4% placebo remission rate.
What malignancy findings worried investors?
On the 50 mg arm, Abivax reported one prostate cancer, one breast cancer, and one colonic dysplasia case (non-NMSC), which investigators called unrelated to treatment. Non-melanoma skin cancers were also reported, mostly in older patients.
When does Abivax plan to file an NDA?
Abivax said it intends to submit a New Drug Application to the U.S. FDA for obefazimod in ulcerative colitis in late fourth quarter 2026, supported by ABTECT induction and 44-week maintenance data.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
